Overview

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Status:
RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

orforglipron